

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM695114

SUBMISSION TYPE:	RESUBMISSION		
NATURE OF CONVEYANCE:	ASSIGNMENT OF THE ENTIRE INTEREST AND THE GOODWILL		
RESUBMIT DOCUMENT ID:	900652715		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
Allergan Therapeutics LLC		05/11/2020	Limited Liability Company: DELAWARE
RECEIVING PARTY DATA			
Name:	Société des Produits Nestlé S.A.		
Street Address:	Avenue Nestlé 55		
City:	Vevey		
State/Country:	SWITZERLAND		
Postal Code:	1800		
Entity Type:	Société Anonyme (Sa): SWITZERLAND		
PROPERTY NUMBERS Total: 1			
Property Type	Number	Word Mark	
Serial Number:	87951412	LET ME BREAK IT DOWN FOR YOU	
CORRESPONDENCE DATA			
Fax Number:			
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
Phone:	303.245.2092		
Email:	ljheld@hollandhart.com, docket@hollandhart.com		
Correspondent Name:	Catherine C. Miller, Holland & Hart LLP		
Address Line 1:	P.O. Box 8749		
Address Line 2:	Attn: Trademark Docketing		
Address Line 4:	Denver, COLORADO 80201-8749		
ATTORNEY DOCKET NUMBER:	82145.2731		
DOMESTIC REPRESENTATIVE			
Name:	Catherine C. Miller, Holland & Hart LLP		
Address Line 1:	P.O. Box 8749		
Address Line 2:	Attn: Trademark Docketing		
Address Line 4:	Denver, COLORADO 80201-8749		
NAME OF SUBMITTER:	Catherine C. Miller		

SIGNATURE:	/Catherine C. Miller/
DATE SIGNED:	12/15/2021
Total Attachments: 1 source=US - DoA (ITU)#page1.tif	

65

Trademark Assignment

WHEREAS, Allergan Therapeutics LLC, a Limited Liability Company of Delaware, with its principal place of business at 5 Giralda Farms, Madison, New Jersey 07940, UNITED STATES OF AMERICA ("Assignor"), owns and has a *bona fide* intent to use the Mark LET ME BREAK IT DOWN FOR YOU ("the Mark") in connection with the following services: "Providing medical information to consumers regarding the treatment and prevention of gastrointestinal disorders; and


WHEREAS, Assignor has applied to register the Mark on the Principal Register of the United States Patent and Trademark Office based on Assignor's *bona fide* intent to use the mark in commerce in connection with the above-described goods and/or services, Application Serial No. 87951412 filed on June 6, 2018; and

WHEREAS, Societe des Produits Nestle S.A., a Swiss Societe Anonyme, with its principal place of business at Avenue Neslte 55, 1800 Vevey, SWITZERLAND ("Assignee"), desires to acquire the business of Assignor in connection with which Assignor has a *bona fide* intent to use the Mark and the pending Application;

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, Assignor hereby sells, assigns and transfers to Assignee all right, title and interest in and to the Mark and the pending Application therefor, together with that portion of Assignor's business in connection with which it has a *bona fide* intent to use the Mark.

Assignor:

Allergan Therapeutics LLC

By: 
Name: Johanna M. Corbin
Title: Assistant Secretary

Effective as of May 11, 2020